3.3. Effectiveness analysis
Treatment with avatrombopag resulted in an increased platelet count, with a mean (SD) change in platelet count from baseline to procedure day (days 8 to 15 after the first dose of avatrombopag, n = 38) of 41.1 × 10Platelet count by study visit. Treatment is defined as the day of initiation of avatrombopag up to and including the day before procedure day. For patients who did not have a platelet count assessment on the day of the procedure, but rather had a platelet count assessed the day prior to the procedure, the platelet count assessed the day prior to the procedure was summarized as a procedure platelet count. N = number, SD = standard deviation.Platelet count at baseline and procedure day by baseline platelet count. For patients who did not have a platelet count assessment on the day of the procedure, but rather had a platelet count assessed the day prior to the procedure, the platelet count assessed the day prior to the procedure was summarized as a procedure platelet count. N = number, SD = standard deviation.The proportion of patients not requiring a platelet transfusion after baseline and up to 7 calendar days following procedure day was 98% (n = 49; 95% CI: 89.4%–99.9%). One patient with a baseline platelet count of 34 × 10